When DNA is coiled up into chromatin, it’s inaccessible to transcription, and genes are therefore silent. When it’s uncoiled, genes are active. This process, normally controlled by methyl groups, is called epigenetics. Chroma Medicine designs programmable epigenetic editors with effector domains that create precise, durable methylation patterns — thus activating, silencing, or tuning expression of targeted genes, in a way that’s safer and more predictable than alternative gene editing approaches that cut or alter DNA sequences.
In The Media
Explore Companies
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules